SAN DIEGO and ATLANTA, June 6, 2012 /PRNewswire/ -- Orexigen ® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, and Sharecare® an interactive health and wellness social platform providing people with access to expert-developed answers, information and programs to live their healthiest life, announce their partnership for WeightMate™, a comprehensive weight management program developed for participants in the Light Study. Delivered through an internet-based platform by accredited health and fitness professionals, WeightMate provides a convenient, progressive nutrition and exercise program with goal setting and tracking tools. The Light Study ( www.lightstudy.com) is a long-term research study designed to assess the cardiovascular health outcomes associated with an investigational drug, Contrave® (naltrexone SR/bupropion SR), which is being evaluated as a new treatment for obesity.
"WeightMate provides participants in the Light Study with a robust coaching and information platform that is designed to help them make changes in their diet and lifestyle to help them lose weight," said Dr. Mike Clark, Chief Science Officer of Sharecare. "We are excited to work with Orexigen to launch WeightMate, which combines Sharecare's digital expertise in providing expert health knowledge and interactive fitness programs with Orexigen's focus on developing safe and effective new treatments for obesity, which is one of the biggest health care problems facing the United States."
"At Orexigen, we believe weight loss medicines should be used with an effective behavior modification program that is designed to help people make the necessary changes in their lifestyle and diet and provides them with the opportunity to optimize their weight loss," said Michael Narachi, CEO of Orexigen. "We partnered with Sharecare to build WeightMate for all participants in the Light Study to provide comprehensive and personalized weight management tools to assist study participants in achieving their health goals. We are very excited to be partnering with Sharecare on WeightMate."About the Light Study The Light Study ( www.lightstudy.com) is a randomized, double-blind, placebo-controlled cardiovascular outcomes trial evaluating the occurrence of major adverse cardiovascular events (MACE) in patients participating in the study. An interim analysis and NDA resubmission is planned once approximately 87 MACE events have occurred, which is anticipated to be less than two years from the start of the trial. If marketing approval is received for Contrave, the trial will continue toward the final analysis in the post-approval setting. It is expected to enroll up to 10,000 study participants at approximately 300 research sites nationwide. About Contrave® Contrave (naltrexone SR/bupropion SR) is an investigational medication being evaluated for weight loss. Contrave has been studied to date in clinical trials enrolling more than 4,500 people and was developed by Orexigen to reduce appetite, help control cravings, increase metabolism and improve control over eating behaviors. Contrave has been shown to help people lose weight and keep it off for up to one year. In previous clinical trials, 53 percent of study participants taking Contrave and 21 percent of those taking placebo lost five percent or more of their body weight over the 12 month trial duration. Those who took Contrave for six months, combined with a structured weight management program, lost an average of 25 pounds, compared with 17 pounds for those using the weight management program and receiving placebo. Many patients saw noticeable improvements in cholesterol levels, and blood sugar control, as well as smaller waistlines. Those who combined Contrave with diet and exercise experienced the most reduction in body weight. There is no guarantee that Contrave will make patients lose weight. Contrave was generally well tolerated in clinical trials. In the Contrave clinical development program, the most frequent adverse events on Contrave were nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea. These were mostly mild to moderate in severity and short in duration.